At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 388 enrolled
Drug / intervention
Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) +1 moredrug
Likely dose
Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode
In Brief
A Phase 3 clinical trial evaluating Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) and Chlorpromazine for Schizophrenia. Completed, enrolled 388 participants across 11 sites.
Detailed Summary
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedApr 16, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.2 years ago
Interventions
Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)drug
200 mg or 300 mg, oral, single dose
Chlorpromazinedrug
50 mg, oral, double dose